Search Results
Jun 01, 2026, 10:00 ET Endeavor Health researchers develop more comprehensive genetic screening for heart disease risk
Translational Research at Endeavor Health. "But when combined, they're even more powerful and can give us a broader view of risk. Think of it like a flashlight vs. a flood light – the flashlight can help you see part of the picture, while a floodlight illuminates the whole landscape." In the U.S., coronary
More news about: Endeavor Health
Jun 01, 2026, 10:00 ET Major Accounting Software Brands Are Invisible in AI Search
NetSuite vs.
More news about: 5W Public Relations
Jun 01, 2026, 10:00 ET Hershey's and Patrick Renna Spark Nationwide Debate Over How to Make the Perfect S'more
moments that create lasting memories across generations and backyards – with Hershey's right at the center.What is the "Camp Gooey vs. Camp Toasty" debate?It is the classic question of how to toast a marshmallow – extra gooey, lightly golden or fully scorched. Hershey's
More news about: The Hershey Company
Jun 01, 2026, 09:00 ET Bridgestone Launches New UltraWeather Tire
UltraWeather tire vs. the Bridgestone WeatherPeak tire, in tire size 225/65R17. Results may vary depending on proper tire and vehicle maintenance, road conditions and driving habits.3 Comparison based on internal testing of the Bridgestone UltraWeather tire vs. the Goodyear
More news about: Bridgestone Americas, Inc.
Jun 01, 2026, 09:00 ET DoubleLine Flexible Income Fund Waives Operating Expenses Across All Share Classes
sovereign and corporate bonds, emerging markets fixed income and U.S. government issues.10-Year Excess Return and Risk-Adjusted Outperformance vs. BenchmarkAll share classes of the Fund – DFLEX (Class I), DLPIX (Class I2), DLINX (Class N), DFFLX (Class R6) – have delivered excess return
More news about: DoubleLine
Jun 01, 2026, 08:41 ET Allstacks Launches Product Studio, a Context-Aware Workspace for Product Teams Building With AI
stranger to build an engine for your car without blueprints and schematics: for what car, how does it work with other components, what parts will be new vs. existing?" said Hersh Tapadia, CEO of Allstacks. "Product Studio now brings the same context and engineering awareness that powers the rest of our platform
More news about: Allstacks
Jun 01, 2026, 08:00 ET Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics
examples in tissue; based on internal Waters testing, protocol and sample details on file.Up to 10x MS/MS sensitivity comparison (Cyclic IMS P20 vs prior generation instrument) based on internal Waters testing; protocol and sample details on file.Upper mass range specification and representative
More news about: Waters Corporation
Jun 01, 2026, 08:00 ET Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics
examples in tissue; based on internal Waters testing, protocol and sample details on file.Up to 10x MS/MS sensitivity comparison (Cyclic IMS P20 vs prior generation instrument) based on internal Waters testing; protocol and sample details on file.Upper mass range specification and representative
More news about: Waters Corporation
Jun 01, 2026, 08:00 ET Salt Security launches Salt Code, the first agentic security solution to enforce security policies inside AI coding assistants
Codex, Gemini CLI, and Antigravity. It plugs into the source control and pipeline tools developers already use, including GitHub, GitLab, Bitbucket, VS Code, any IDE supporting MCP server configuration, and major CI/CD platforms. Workflow integrations with Jira and ServiceNow route findings into the
More news about: Salt Security
Jun 01, 2026, 08:00 ET Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult Patients with Complicated Urinary Tract Infection Including Pyelonephritis
ZAYNICH demonstrated higher combined clinical cure and microbiologic response (composite endpoint) at the test of cure (TOC) visit versus meropenem, 89.0% vs 68.4% respectively and was generally well toleratedMore than 2.8 million antimicrobial-resistant infections occur each year
More news about: Wockhardt
Jun 01, 2026, 07:30 ET Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
model (Bexorg BrainEx platform, physiologically reactivated brains from human donors); preferential metabolic rescue in Alzheimer's disease donor brains vs controlsExhibits robust beneficial effects across a spectrum of preclinical models of Alzheimer's, and multiple sclerosis: restores metabolic
More news about: Biohaven Ltd.
Jun 01, 2026, 07:25 ET GOFO op DELIVER Europe 2026 als genomineerde voor de Rising Star Award
opgericht in de Verenigde Staten in 2023, is een technologiegedreven logistiek netwerk voor de last-mile dat winkeliers en consumenten bedient in de VS, Frankrijk, Nederland en Italië. Geleid door de merkfilosofie "Drive Efficiency, Deliver Trust", combineert GOFO geavanceerde technologie met lokale operaties
More news about: GOFO
Jun 01, 2026, 07:00 ET Eisai and CaringKind Launch New Initiative to Address Mealtime and Nutrition Needs for People Living with Alzheimer's Disease and Related Dementias
X) pages. References:Baker LD, Espeland MA, Whitmer RA, et al. Structured vs self-guided multidomain lifestyle interventions for global cognitive function: The US POINTER randomized clinical trial. JAMA 2025;334(8):681-691.2026
More news about: Eisai Inc.
Jun 01, 2026, 06:00 ET Phothera® Supports Vitiligo Awareness Month with "Shine a Light on Vitiligo" Campaign
with built-in safety guardrails, validated by the 783-patient LITE Study showing 3x higher adherence with home NB-UVB phototherapy versus in-office (51% vs 16%).² Through Phothera Cares, cost and geography are not barriers to care.The campaign will feature a live webinar on June 25, "Practical Decisions
More news about: Phothera
Jun 01, 2026, 03:04 ET China's Original Innovative Drug Cipepofol Approved for Marketing by the U.S. FDA
Ni T, Zhou X, Wu S, et al. Hemodynamic Impact of Cipepofol vs Propofol During Anesthesia Induction in Patients With Severe Aortic Stenosis: A Randomized Clinical Trial. JAMA Surg. 2025;14.9(IF).Yu Y, Deng J, Yin Y,et al. Ciprofol vs propofol for gastrointestinal endoscopy sedation: a systematic
More news about: Haisco
Jun 01, 2026, 03:00 ET OpenSpace Surpasses 1,000 Data Center Projects, Defining the Construction Intelligence Standard for AI Infrastructure
5X more quality issues captured; 10X faster documentation; and a 5-week average payback period – while giving teams real-time visibility into actual vs. planned progress across complex, multi-phase builds, and faster resolution of the issues that threaten schedules and budgets.A recent data center
More news about: OpenSpace
Jun 01, 2026, 01:51 ET Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
regimen combined with transarterial chemoembolization (TACE) significantly prolongs median PFS compared to TACE alone (by BIRC per mRECIST, 11.1 months vs. 8.3 months), supporting the potential use of this combination approach in patients with unresectable hepatocellular carcinoma (uHCC).Urological
More news about: Hengrui Pharma
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
confirmed ORR (cORR) of 81.8% (95% CI: 59.7-94.8) and DCR of 100%The second stage of the PoC study is ongoing in head-to-head comparison vs. pembrolizumab plus chemotherapy in the first-line treatment of advanced NSCLC (all PD-L1 expression levels)Innovent and Takeda are co-developing
More news about: Innovent Biologics
May 31, 2026, 17:36 ET Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
understanding of the long-term impact of VORANIGO for the glioma community."A global, randomized, double-blinded, Phase 3 trial of vorasidenib vs placebo in patients with grade 2 glioma with an IDH1/2 mutation (INDIGO): updated efficacy and safety – Sunday, May 31, 4:36 - 4:42 p.m. CDTKey
More news about: Servier Pharmaceuticals
May 31, 2026, 09:00 ET HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
received immunotherapy: 13.9% in the treatment group vs 19.2% in the control group; proportions receiving targeted therapy: 12.4% vs 17.3%; proportions receiving ADC therapy: 4.5% vs 5.6%; proportions participating in other clinical trials: 0.8% vs 2.3%.Favorable safety profile comparable to
More news about: Akeso, Inc.
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
doi:10.1016/j.oraloncology.2025.10779110 Haddad R, et al. OrigAMI-5: A randomized, phase 3 study of amivantamab plus pembrolizumab and carboplatin vs standard of care pembrolizumab plus platinum and 5-fluorouracil as first-line treatment in recurrent/metastatic head and neck cancer. Presented at: The
More news about: Johnson & Johnson
May 31, 2026, 08:27 ET Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
described as macular or maculopapular. Adverse reactions of rash were 26% with ERLEADA vs 8% with placebo. Grade 3 rashes (defined as covering >30% body surface area [BSA]) were reported with ERLEADA treatment (6%) vs placebo (0.5%).The onset of rash occurred at a median of 83 days. Rash resolved
More news about: Johnson & Johnson
May 31, 2026, 08:01 ET Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
(20% vs 3.1%), electrocardiogram QT prolonged (9% vs 0%), fatigue (3.2% vs 5%), edema (2.5% vs 0%), rash (1.9% vs 1.0%), diarrhea (1.3% vs 2.0%), abdominal pain (0.6% vs 2.0%), pyrexia (0.6% vs 0%), COVID19 infection (0.6% vs 0%), constipation (0% vs 1.0%), nausea (0% vs 1.0%), vomiting (0% vs 1.0%),
More news about: Eli Lilly and Company
May 30, 2026, 08:05 ET ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases
endpoints1GammaTile demonstrated lower rates of surgical bed regrowth (SBR) at 12-months compared to standard radiation therapy (1.0% vs. 11.9%).Patients who received GammaTile had a greater than 50% reduction in risk of either tumor recurrence or death compared to standard of
More news about: GT Medical Technologies
May 30, 2026, 08:00 ET GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
rounds. The five-year survival rates in England are significantly higher in Stage III than Stage IV for each of these cancers: 24.7% vs 6.2% for esophageal cancer, 64.2% vs 11.0% for colorectal cancer."For most cancer patients, there is a real difference between being diagnosed and being treated
More news about: GRAIL, Inc.